Furthermore, in all the cancer cell line models that we tested in the immunodeficient mice, Ehmt2 loss alone was either less effective or not sufficient to induce tumor suppression, indicating that anti-tumor immunity, particularly NK cell-mediated cytotoxicity triggered by Ehmt2 loss, was key to in vivo tumor suppression. This evidence concerns the gene EHMT2 and cancer.